In April 2024, we first learned that The Cabin in the Woods and Bad Times at the El Royale filmmaker Drew Goddard had signed up to helm a new Matrix movie for Warner Bros. Rumours of a reboot or ...
Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...
Indonesian production company Forka Films has unveiled a production consortium for auteur Kamila Andini’s upcoming feature “Four Seasons in Java,” scheduled for 2026 release. The announcement came at ...
I recently drove the new 2026 Audi Q3 and was amazed by how well-put-together it was, especially for an entry-level crossover from a German luxury automaker. One of the features that stood out was the ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. This article explores that question through ...
Oracle’s Java team sat down with me last week for a fast-moving briefing on Java 25 and the broader direction of the platform. The headline: JDK 25 is an LTS release, the second on Oracle’s new ...
In 1971, German mathematicians Schönhage and Strassen predicted a faster algorithm for multiplying large numbers, but it remained unproven for decades. Mathematicians from Australia and France have ...
Hosted on MSN
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results